ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Nashville, TN, USA:

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:Part A - first in human ...

Active, not recruiting
Multiple Sclerosis (MS)
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: ANK-700

Phase 1

Anokion

Franklin, Tennessee, United States and 14 other locations

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

Phase 3

Celgene
Celgene

Franklin, Tennessee, United States and 60 other locations

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The s...

Active, not recruiting
Multiple Sclerosis, Relapsing
Drug: Ocrelizumab

Phase 4

Genentech
Genentech

Nashville, Tennessee, United States and 30 other locations

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the tre...

Active, not recruiting
Multiple Sclerosis
Cerebrovascular Accident
Drug: Phase 3; MYOBLOC
Drug: Phase 2; Placebo

Phase 2, Phase 3

Supernus Pharmaceuticals
Supernus Pharmaceuticals

Nashville, Tennessee, United States and 8 other locations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

relapse rate (ARR) in participants with relapsing forms of MSSecondary Objective:To assess efficacy of SAR442168 compared to teriflunomide (...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo to match Teriflunomide
Drug: Teriflunomide HMR1726

Phase 3

Sanofi
Sanofi

Franklin, Tennessee, United States and 185 other locations

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab
Drug: Methylprednisolone

Phase 3

Roche
Roche

Nashville, Tennessee, United States and 154 other locations

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple...

Active, not recruiting
Multiple Sclerosis, Primary Progressive
Drug: Placebo matched to ocrelizumab
Drug: Fenebrutinib

Phase 3

Roche
Roche

Nashville, Tennessee, United States and 192 other locations

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple...

Enrolling
Primary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo

Phase 3

Sanofi
Sanofi

Franklin, Tennessee, United States and 291 other locations

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMSSecondary Objective:To evalu...

Active, not recruiting
Secondary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo to match Tolebrutinib

Phase 3

Sanofi
Sanofi

Franklin, Tennessee, United States and 300 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems